🚀 VC round data is live in beta, check it out!
Aton Valuation Multiples
Discover revenue and EBITDA valuation multiples for Aton and similar public comparables like ExpreS2ion Biotech, Pila Pharma, Vivesto, Instituto Rosenbusch and more.
Aton Overview
About Aton
Aton is a biopharmaceutical company that foresees a focused future of medicine. The company specializes in the main businesses: Inoviem Scienfic and B Cell Design. The company's services include pre-clinical and Clinical Services, Monoclonal Antibodies Production, Laboratory equipment Production, and Human Tissue Provision.
Founded
1998
HQ
Employees
9
Website
Sectors
Financials (FY)
EV
$11M
Aton Financials
Aton reported last fiscal year revenue of $706K and negative EBITDA of ($25K).
In the same fiscal year, Aton generated $565K in gross profit, ($25K) in EBITDA losses, and had net loss of ($1M).
Aton P&L
In the most recent fiscal year, Aton reported revenue of $706K and EBITDA of ($25K).
Aton expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $706K | XXX | XXX | XXX |
| Gross Profit | — | XXX | $565K | XXX | XXX | XXX |
| Gross Margin | — | XXX | 80% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($25K) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (4%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (28%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($1M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (179%) | XXX | XXX | XXX |
| Net Debt | — | — | $3M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Aton Stock Performance
Aton has current market cap of $6M, and enterprise value of $11M.
Market Cap Evolution
Aton's stock price is $0.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $11M | $6M | 0.0% | XXX | XXX | XXX | $-0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAton Valuation Multiples
Aton trades at 15.0x EV/Revenue multiple, and (418.4x) EV/EBITDA.
Aton Financial Valuation Multiples
As of March 18, 2026, Aton has market cap of $6M and EV of $11M.
Equity research analysts estimate Aton's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Aton has a P/E ratio of (4.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6M | XXX | $6M | XXX | XXX | XXX |
| EV (current) | $11M | XXX | $11M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 15.0x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (418.4x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (54.5x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 18.7x | XXX | XXX | XXX |
| P/E | — | XXX | (4.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 328.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Aton Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Aton Margins & Growth Rates
Aton's revenue in the last fiscal year grew by 60%.
Aton Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 60% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (4%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (95%) | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 9% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 108% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Aton Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| ExpreS2ion Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Pila Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivesto | XXX | XXX | XXX | XXX | XXX | XXX |
| Instituto Rosenbusch | XXX | XXX | XXX | XXX | XXX | XXX |
| Genxone | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Aton M&A Activity
Aton acquired XXX companies to date.
Last acquisition by Aton was on XXXXXXXX, XXXXX. Aton acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Aton
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAton Investment Activity
Aton invested in XXX companies to date.
Aton made its latest investment on XXXXXXXX, XXXXX. Aton invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Aton
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Aton
| When was Aton founded? | Aton was founded in 1998. |
| Where is Aton headquartered? | Aton is headquartered in France. |
| How many employees does Aton have? | As of today, Aton has over 9 employees. |
| Is Aton publicly listed? | Yes, Aton is a public company listed on Euronext Paris. |
| What is the stock symbol of Aton? | Aton trades under ALTAO ticker. |
| When did Aton go public? | Aton went public in 2007. |
| Who are competitors of Aton? | Aton main competitors are ExpreS2ion Biotech, Pila Pharma, Vivesto, Instituto Rosenbusch. |
| What is the current market cap of Aton? | Aton's current market cap is $6M. |
| What is the current revenue of Aton? | Aton's last fiscal year revenue is $706K. |
| What is the current EV/Revenue multiple of Aton? | Current revenue multiple of Aton is 15.0x. |
| Is Aton profitable? | No, Aton is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.